Antoxis is a chemistry-led platform company, which has recently achieved major R&D milestones and the granting of patents to protect its novel molecular technology in key territories, including the USA.
The company is focused on developing innovative approaches to the treatment of neurodegenerative conditions, cancer, inflammatory disorders and cardiovascular disease.
Antoxis aims to address these areas of major unmet need by using its proprietary knowledge to develop redox-active compounds that act at the level of the cell mitochondria to influence tumour cell metabolism or to disrupt the cycle of oxidative stress; mitochondrial dysfunction; free radical damage; cell death which is a significant feature of many degenerative conditions.
The company’s therapeutics programme is complemented by a regenerative medicine initiative in which small molecules from its technology platform are being developed to influence redox-sensitive cell processes and to increase the viability of transplanted cells by affording protection against reperfusion damage.
Antoxis’ objective has been to secure as much patent space as possible to protect hundreds of thousands of synthetic structures derived from the natural flavonoid molecular scaffold to produce compounds with substantially improved activities and pharmaceutical properties for therapeutic and stem cell applications. This has been achieved through the company’s proprietary chemistry knowledge and structure-activity data provided by its internal R&D programme. Exemplification of the company's platform technology has been further enhanced by carefully chosen academic and commercial partners.
In addition to maintaining its lead position in this field, Antoxis is currently focused on increasing the value of its intellectual property assets by generating compound efficacy data in a range of disease state models covering cancer, neurodegenerative and cardiovascular conditions as well as regenerative medicine applications. On the basis of these studies, the company will choose the most compelling compound and clinical indication combinations to move forward into clinical Phase I studies to maximise value to its investors.
Antoxis has two granted patents, including the US, covering composition of matter and use of its compounds. Two further applications have been filed to protect new molecular design concepts and regenerative medicine use. The Antoxis patent estate carves out a swathe of IP protecting hundreds of thousands of synthetic variants of the flavonoid family.
The unique properties and activities of compounds already developed by Antoxis confirm that the company's proprietary technology platform provides an exceptional resource for drug development.